(c) what steps have been taken to rectify the situation and fix responsibility?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) to (c) Earlier the policy was to fix the price of formulations on the basis of the notified price of the bulk drug involved. However, it has now been decided to fix the prices of formulations on the basis of the purchased price or the notified price, whichever is lower.

Drug Units in the Small Scale Sector

655. SHRI K. G. MAHESWARAPPA:
SHRIMATI SATYA BAHIN:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what are the names of Hoechst, Fair Deal Corporation, German Remedies and Cadila groups of companies which are operating as Small Scale Sector units and getting exemption from price control;

(b) what are the names of products which are being sold under exempted category and who owned the brand names earlier; and

(c) how far the price exemption notification is applicable to these units?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) to (c) The position is being ascertained and will be laid on the Table of the House.

Reassessment of Liabilities against Drug Companies

656. SHRI G. G. SWELL:
CHOWDHARY RAM SEWAK:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unrtarred Question 1316 given in the Rajya Sabha on the 7th January, 1991 and state:

(a) whether it is a fact that after review, the amount due against 11 companies have gone up from Rs. 50 crores to Rs. 115 crores upto 1983; and

(b) what is the tentative amount due from each company as worked out after review and what is the total amount still to be recovered?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) and (b) Yes, Sir. The revised amounts upto 1983 in respect of companies involved in the Supreme Court case and Glaxo Labs. tentatively stand at around Rs. 115 crores after review. A statement giving the details is enclosed.

Statement

(In lakhs)

Sl. No.	Name of the Company	Amount due	Amount already paid	Balance amount recoverable
1	2	3	4	5
1	M/s. Cyanamid India Ltd.	536·91	100·00	436·91
2	M/s. Hoechst India Ltd.	2491·05	312·10	2178·95
3	M/s. John Wyeth India +M/s. Geoffrey Manners Ltd.	206·04	45·00	161.04
4	M/s. Ethnor Ltd.	10·19	10·19	Nil

1	2	3	4	5
5	M/s. Franco Indian Pharmaceuticals	14·02	0·43	13·59
6	M/s. Pfizer Ltd.	87·61	19·90	67·71
7	M/s. Anil Starch Products	11·61	Nil	11·61
8	M/s. S. G. Pharmaceuticals	205·36	Nil	205·36
9	M/s. Tamilnadu Dadha Pharmaceuticals	37·97	Nil	37·97
10	M/s.Merind Ltd.	781·58	Nil	781·58
11	M/s. Glaxo Labs.	7178·18	819·00	6359·13
		11560·52	1306·62	10253·90

Fixation of Prices of Bulk Drugs and their Formulation

657. SHRI MOHD. KHALEELUR RAHAMAN: Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 402 given in the Rajya Sabha on the 31st December, 1990 and state:

(a) whether it is a fact that there are certain drugs which are imported as well as indigenously produced;

(b) what are the names of these drugs and on what basis their formulation are fixed;

(c) what is the indigenous price and landed cost of import of each;

(d) whether it is a fact that formulations based on Sulphamoxole, Zinc Bacitiracin Ethisterone Novgestrol, Polymixio 'B' Sulphate and Thioridazine are being sold at very high prices;

(e) what is the bulk drug price taken for fixation of the formulation prices; and

(f) by when the prices of bulk drugs would be fixed?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) Yes, Sir.

(b) and (c) The requisite information to the extent available would be collected and will be laid on the Table of the House.

(d) All these bulk drugs have been brought under price control under Category II of DPCO, 1987. The prices of formulations based on Sulphamaxole, Zinc Bactitracin, Polymixin 'B' Sulphate and Thioridazine have already been fixed in accordance with the provisions contained in the DPCO, 1987. BICP has been requested to workout the prices of formulations based on Ethisterone and Novgestrol on *suo moto* basis.